UNSPSC 51111909: Methyl aminolevulinate

This classification denotes a photosensitizing agent with the molecular formula C6H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 585NM85KYM, chemically known as pentanoic acid, 5-amino-4-oxo-, methyl ester but generally known as methyl aminolevulinate, which bears US NIH Compound Identifier 157922. European Medicines Agency schedules Methyl aminolevulinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22645.

World Health Organization schedules methyl aminolevulinate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METHYL AMINOLEVULINATE remains the US FDA Preferred Term for this commodity. Methyl aminolevulinate bears US NLM identifiers UMLS ID C1134467 and NCI Concept Code C76305. SMILES: O(C(=O)CCC(=O)CN)C.

UNSPSC 51111909 Methyl aminolevulinate, a Commodity code, encompasses pharmaceutical active ingredients and specialty compounds purchased by state and local health agencies, primarily through health benefit programs and pharmacy benefit initiatives. The Texas Health and Human Services Commission's April 2026 Request for Information regarding direct-to-manufacturer prescription programs signals state procurement interest in establishing alternative supply channels for pharmaceutical products, including specialty compounds, outside traditional pharmacy benefit manager and group purchasing organization arrangements. State and local governments acquire these materials as part of broader pharmacy benefit management operations serving employee health plans, Medicaid programs, and state agency workforces, with procurement focused on cost management, outcomes-based contracting, and negotiated net pricing models that replace traditional rebate structures.

The most recent documented activity appears limited to exploratory market research rather than active purchasing. The Texas Health and Human Services Commission's RFI (HHS0017013) posted April 3, 2026, represents preliminary vendor outreach to inform future formal solicitation strategy rather than an immediate procurement opportunity; no award value, budget range, or formal competitive timeline was specified. The RFI sought vendor capability information regarding direct pharmaceutical contracting, value-based agreements, and fulfillment capacity for self-insured employers and government health plans. No other recent state or local opportunities under this specific Commodity code appear in the available data, suggesting that direct procurement of methyl aminolevulinate or related specialty pharmaceutical ingredients through state and local formal solicitation remains minimal or occurs through broader pharmacy benefit contracts tagged to higher-tier UNSPSC codes rather than this specific ingredient designation.